Trial Profile
A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Lymphoid leukaemia; Richter's syndrome; T-cell prolymphocytic leukaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Acerta Pharma
- 29 Nov 2023 According to an AstraZeneca media release, analysis of 5 studies (CL-001, CL-003, CL-006, CL-007 & CL-309) showing acceptable safety outcomes based on rates of nonfatal and fatal ventricular arrhythmias and sudden death in patients with CLL will be presented at 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
- 14 Jul 2023 Planned End Date changed from 15 Jul 2026 to 6 Sep 2027.
- 13 Dec 2022 Final results of treatment naive cohort were presented at the 64th American Society of Hematology Annual Meeting and Exposition.